Diphtheria Vaccine Market Size to Exceed USD 9,009.8 Mn by 2032

The Diphtheria Vaccine Market, estimated at USD 6,047.7 Mn in 2025, is expected to exhibit a CAGR of 5.86% and reach USD 9,009.8 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The increase in the prevalence of diphtheria cases among migrants in Europe is expected to drive the growth of global diphtheria vaccine market over the forecast period. For instance, according to European Centre for Disease Prevention and Control (ECDC), a European government organization, published on December 5, 2025, since the beginning of 2025, and as of December 2, 2025, 154 cases of diphtheria have been reported by eight EU/EEA countries including Germany, Austria, Belgium, France, and others.

Global Diphtheria vaccine Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

Furthermore, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources which were required to ensure safety in hospitals and provide treatment to patients with other diseases. This has impacted the overall healthcare market negatively.

During the COVID 19 pandemic, the diphtheria vaccine market was significantly impacted due to increase in the demand for vaccines and decrease in the supply for diphtheria vaccines due to restrictions imposed by government during COVID-19. For instance, according to the WHO (world health organization), on May 22, 2025, it is estimated that 80 million children are under risk of at least one of such diseases such as diphtheria, measles and polio as COVID-19 disrupts routine vaccination.

Global Diphtheria vaccine Market: Key Developments

In June 2025, Merck & Co., Inc., an American multinational pharmaceutical company, announced that they and Sanofi, a French multinational pharmaceutical and healthcare company, have launched a Six-in-One Pediatric Combination Vaccine for diphtheria in the U.S.

In September 2025, Serum Institute of India Pvt. Ltd., an Indian biotechnology and biopharmaceuticals company, announced that company has submitted its phase 2-3 clinical trial data to the Drugs Control General of India (DCGI)’s expert panel seeking permission to manufacture the vaccines for Diphtheria, Pertussis, and Tetanus (Tdap).

Browse 34 Market Data Tables and 30 Figures spread through 190 Pages and in-depth TOC on “Global Diphtheria vaccine Market”- Forecast to 2032, by Vaccine Type (DTaP vaccine, DT vaccine, Tdap vaccine, and Td vaccine), by Age Group (Pediatrics and Adults), by End User (Hospitals, Clinics, and Vaccination Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/diphtheria-vaccine-market-5480

Key Takeaways of the Global Diphtheria vaccine Market:

• The global diphtheria vaccine is expected to exhibit a CAGR of 5.86% during the forecast period due to the increasing government initiatives such as to provide diphtheria vaccines to Ukraine. For instance, in October 2025, United Nations Children's Fund (UNICEF), a government organization in the U.S. announced that they will provide 700,000 doses of tetanus-diphtheria (Td) vaccine to protect children of age six and above and adults in Ukraine.
• Among vaccine type, DTaP vaccine segment is estimated to hold a dominant position in the global diphtheria vaccine over the forecast period, owing to the large number of vaccine manufactured by key market players fall into this segment, such as boostagen, a Tetanus Toxoid, Reduced Diphtheria Toxoid, Recombinant Acellular Pertussis Vaccine manufactured by BIONET-ASIA, a vaccines manufacturing company.
• Among Age Group, pediatrics segment is estimated to hold a dominant position in the global diphtheria vaccine over the forecast period, due to the higher susceptibility of kids to diphtheria.
• Major players operating in the global diphtheria vaccine include AJ Vaccines A/S., BIONET-ASIA, GlaxoSmithKline plc., MassBiologics, Meiji Holdings Co., Ltd., Merck & Co., Inc, Panacea Biotec, Sanofi, Serum Institute of India Pvt. Ltd., Bharat Biotech, and BB – NCIPD Ltd.